insulin secretagogues peptides (incretins)  


Trial Studied trt Control trt patientstagsNCTROB Result

diabetes type 2

Seino, 2009albiglutideplaceboNCT00530309Exploratory negative
Rosenstock (30 mg every two weeks), 2009albiglutide biweeklyplacebo (add on MET)NCT00518115Low risk of bias suggesting
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET)NCT00518115Exploratory suggesting
HARMONY 7 (114179) ongoing albiglutideliraglutideNCT01128894 ongoing
NN2211-1333liraglutide other doses -
Pratley (1.8 vs 1.2), 2010liraglutide 1.8mgliraglutide 1.2mgnegative
LEADER, 2016liraglutideplaceboNCT01179048Low risk of bias suggesting
Seino, 2008liraglutide other dosesplaceboNCT00154414Exploratory negative
Madsbad (vs placebo), 2004liraglutide other dosesplacebonegative
Harder, 2004liraglutide other dosesplaceboExploratory -
NN2211-1571 (Vilsbøll), 2007liraglutide other dosesplaceboNCT00154401Exploratory negative
Kaku 0.6mg, 2010liraglutide other dosesplaceboLow risk of bias suggesting
LIBRA ongoing liraglutide other dosesplaceboNCT01270789Low risk of bias ongoing
NN2211-1800 ongoing liraglutide other dosesplaceboNCT00943501Low risk of bias ongoing
NCT00978393 ongoing liraglutide other dosesplaceboNCT00978393Low risk of bias ongoing
NN2211-1799 ongoing liraglutide other dosesplaceboNCT00620282Low risk of bias ongoing
NN2211-3619 ongoing liraglutide other dosesplaceboNCT01206101 ongoing
NN8022-1923 ongoing liraglutide other dosesplaceboNCT00781937Low risk of bias ongoing
NN8022-1922 ongoing liraglutide other dosesplaceboNCT01272232Low risk of bias ongoing
LEAD-2 (Nauck) (1.2mg vs placebo), 2009liraglutide 1.2mgplacebo (add on MET)NCT00318461Low risk of bias suggesting
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)NCT00318461Low risk of bias suggesting
NN2211-1796liraglutide other dosesplacebo (add on MET)NCT00614120 -
NCT01234649 ongoing liraglutide other dosesplacebo (add on MET)NCT01234649Low risk of bias ongoing
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NCT00395746Low risk of bias ongoing
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)NCT00331851Low risk of bias suggesting
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)NCT00333151Low risk of bias suggesting
Kaku 0.9mg, 2010liraglutide other dosesplacebo (on top SU)Low risk of bias suggesting
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NCT01296412 ongoing
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SUNCT00518882Risk of bias suggesting
Seino, 2010liraglutide other dosesglibenclamideNCT00393718Low risk of bias negative
LEAD-3 mono 1.2mg (Garber), 2009liraglutide 1.2mgglimepirideNCT00294723Low risk of bias negative
LEAD-3 mono 1.8mg (Garber), 2009liraglutide 1.8mgglimepirideNCT00294723Low risk of bias negative
Madsbad (vs Glimepiride), 2004liraglutide other dosesglimepirideExploratory suggesting
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009liraglutide 1.2mgglimepiride (add on MET)NCT00318461Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NCT00318461Low risk of bias negative
EAGLE ongoing liraglutide other dosesinsulin glargineNCT01117350 ongoing
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)NCT00331851Risk of bias negative
LEAD 1 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 2 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 4 (1.8 vs 1.2), 2009liraglutide 1.8mgliraglutide 1.2mgnegative
Feinglos, 2005liraglutide other dosesmetforminExploratory negative
LEAD-1 SU (1.2 vs rosiglitazone), 2009liraglutide 1.2mgrosiflitazonesuggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)NCT00318422Low risk of bias suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptinNCT00700817Risk of bias suggesting
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptinNCT00700817Low risk of bias suggesting
GETGOAL-MONO Japan LTS ongoing lixisenatidecontrolNCT00905255 ongoing
ELIXA (EFC11319) ongoing lixisenatideplaceboNCT01147250Low risk of bias ongoing
GETGOAL-MONO ongoing lixisenatideplaceboNCT00688701Low risk of bias ongoing
GETGOAL-Llixisenatideplacebo (add on basal insulin)NCT00715624Low risk of bias -
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin)NCT00975286Low risk of bias ongoing
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin)NCT00866658Low risk of bias ongoing
Ratner DRI6012, 2010lixisenatideplacebo (add on MET)NCT00299871Exploratory -
GETGOAL-F1 ongoing lixisenatideplacebo (add on MET)NCT00763451Low risk of bias ongoing
GETGOAL-M ongoing lixisenatideplacebo (add on MET)NCT00712673Low risk of bias ongoing
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU)NCT01169779Low risk of bias ongoing
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET)NCT00713830Low risk of bias ongoing
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET)NCT00763815Low risk of bias ongoing
GetGoal-X ongoing lixisenatideexenatideNCT00707031Exploratory ongoing
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET)NCT00976937Low risk of bias ongoing
BC20750 ongoing taspoglutideplaceboNCT00744926Low risk of bias ongoing
BC21713 (vs placebo) ongoing taspoglutideplaceboNCT00754988Low risk of bias ongoing
BC20963 ongoing taspoglutideplaceboNCT00744367Low risk of bias ongoing
BP21572 ongoing taspoglutideplaceboNCT00809705Low risk of bias ongoing
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplaceboNCT00423501Exploratory suggesting
Nauck 20 every 2 weeks vs PBO, 2009taspoglutide 20mg once every 2 weeksplacebosuggesting
Nauck 20 once weekly vs PBO, 2009taspoglutide 20mg once weeklyplacebosuggesting
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET)NCT00460941Exploratory suggesting
BC22092 ongoing taspoglutideplacebo (add on MET)NCT00823992Low risk of bias ongoing
NC25113 ongoing taspoglutideplacebo add on standard treatmentNCT01018173Low risk of bias ongoing
BC21625 ongoing taspoglutideexenatideNCT00717457 ongoing
ZC22565 ongoing taspoglutideinsulin glargineNCT01051011 ongoing
BC20965 ongoing taspoglutideinsulin glargine (add on MET)NCT00755287 ongoing
BC21893 ongoing taspoglutidepioglitazoneNCT00909597Low risk of bias ongoing